Physician profile
Robert John Bolster
NPI 1033227723
$9,575.25
in general payments reported to CMS, 2019-2025
34 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,351 · 2020: $1,198 · 2021: $1,559 · 2022: $926 · 2023: $1,054 · 2024: $1,286 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,541.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,568.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,520.97 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $1,123.59 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amarin Pharma, INC. | $698.03 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $457.91 | 2019-2024 | Ofev |
| Amgen INC. | $400.11 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $358.90 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $266.90 | 2021-2025 | Ubrelvy |
| Sanofi-Aventis U.S. LLC | $229.57 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $189.93 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $185.40 | 2025 | Caplyta |
| Dexcom, INC. | $184.00 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $179.91 | 2021 | |
| Nevro Corp. | $175.94 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $169.72 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $89.26 | 2023-2024 | |
| Optinose US, INC. | $88.23 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.72 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.24 | 2020 | |
| Shield Therapeutics INC | $60.33 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $57.03 | 2022 | |
| Exact Sciences Corporation | $52.75 | 2024-2025 | Cologuard Collection Kit |
| Shire North American Group INC | $52.54 | 2019 | |
| Biomerieux INC | $50.74 | 2025 | Filmarray Torch Module |
| Novartis Pharmaceuticals Corporation | $44.59 | 2019-2022 | |
| Corcept Therapeutics | $41.48 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.96 | 2020-2024 | Relistor |
| Tris Pharma INC | $28.88 | 2025 | Dyanavel Xr |
| Pulmonx Corporation | $23.89 | 2022 | |
| Merck Sharp & Dohme LLC | $23.45 | 2019 | |
| Eisai INC. | $21.80 | 2021 | |
| Phadia US INC. | $18.77 | 2024 | Immunocap |
| Adlon Therapeutics L.P. | $16.24 | 2021 | |
| Allergan, INC. | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bolster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.